Psychiatric Adverse Effects From Prucalopride in a Medically Complex Adolescent.

IF 0.7 Q4 PEDIATRICS
Case Reports in Pediatrics Pub Date : 2025-04-01 eCollection Date: 2025-01-01 DOI:10.1155/crpe/6639748
Clare Hawkes, Jonathan J Chandran, Kasia Kozlowska
{"title":"Psychiatric Adverse Effects From Prucalopride in a Medically Complex Adolescent.","authors":"Clare Hawkes, Jonathan J Chandran, Kasia Kozlowska","doi":"10.1155/crpe/6639748","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Prucalopride is a highly selective, 5-HT4 receptor agonist that can be used for the treatment of chronic constipation in individuals for whom laxatives fail to provide adequate relief. The current case study describes adverse neuropsychiatric symptoms following the administration of prucalopride in a 15-year-old female with a complex physical and mental health history to manage chronic constipation. <b>Case Summary:</b> A single 2 mg dose of prucalopride was prescribed to a 15-year-old female to manage her chronic constipation due to a diagnosis of autoimmune enteric neuropathy. Following the oral administration of prucalopride, the patient started experiencing visual and auditory hallucinations, along with suicidal ideation. Prucalopride was ceased, with the patient receiving psychopharmacology and psychological intervention to address the acute onset psychiatric symptoms. <b>Practical Implications:</b> To our knowledge, this is the second documented case of acute onset neuropsychiatric symptoms following the administration of prucalopride. Clinicians should be aware of this possible side effect, particularly if considering administering prucalopride in patients with neurodevelopmental and psychiatric comorbid histories. Increased supervision and monitoring is recommended in these patients if prucalopride is administrated.</p>","PeriodicalId":9623,"journal":{"name":"Case Reports in Pediatrics","volume":"2025 ","pages":"6639748"},"PeriodicalIF":0.7000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11978475/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Pediatrics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/crpe/6639748","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"PEDIATRICS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Prucalopride is a highly selective, 5-HT4 receptor agonist that can be used for the treatment of chronic constipation in individuals for whom laxatives fail to provide adequate relief. The current case study describes adverse neuropsychiatric symptoms following the administration of prucalopride in a 15-year-old female with a complex physical and mental health history to manage chronic constipation. Case Summary: A single 2 mg dose of prucalopride was prescribed to a 15-year-old female to manage her chronic constipation due to a diagnosis of autoimmune enteric neuropathy. Following the oral administration of prucalopride, the patient started experiencing visual and auditory hallucinations, along with suicidal ideation. Prucalopride was ceased, with the patient receiving psychopharmacology and psychological intervention to address the acute onset psychiatric symptoms. Practical Implications: To our knowledge, this is the second documented case of acute onset neuropsychiatric symptoms following the administration of prucalopride. Clinicians should be aware of this possible side effect, particularly if considering administering prucalopride in patients with neurodevelopmental and psychiatric comorbid histories. Increased supervision and monitoring is recommended in these patients if prucalopride is administrated.

普芦卡必利对一个医学复杂青少年的精神不良反应。
背景:普鲁卡必利是一种高选择性的5-HT4受体激动剂,可用于治疗泻药不能提供足够缓解的慢性便秘患者。目前的病例研究描述了一名15岁女性服用普芦卡必利治疗慢性便秘后出现的不良神经精神症状,该女性有复杂的身体和精神健康史。病例总结:一名15岁女性因诊断为自身免疫性肠性神经病变而慢性便秘,单剂量2 mg普鲁卡必利治疗。口服普鲁卡必利后,患者开始出现视觉和听觉幻觉,并产生自杀念头。停用普鲁卡必利,患者接受精神药理学和心理干预,以解决急性发作的精神症状。实际意义:据我们所知,这是第二个记录的病例急性发作的神经精神症状后普卡必利的管理。临床医生应该意识到这种可能的副作用,特别是在考虑给有神经发育和精神共病史的患者服用普卡必利时。如果给予普鲁卡必利,建议对这些患者加强监督和监测。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
11.10%
发文量
48
审稿时长
13 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信